OCGN
Ocugen, Inc.
1.28
+
0.10
8.47%
53 x 1.26
53 x 1.29
bid
ask
53 @ 04:00 PM
1.27-0.01 (0.79%)
Bearish
171
Bullish
419
sentiment
1.19
day range
1.31
0.36
52 week range
1.88
Prev Close1.18
Open1.19
Low1.19
High1.31
Volume5.36M
Avg. Volume9.33M
Market Cap329.38M
Inst. Own10.34%
Beta3.74
Short Ratio3.22
Div & Yield0.00 /
EPS-0.26
P/E0.00
1yr Target5.67
50day MA1.25
200day MA0.66
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
The Globe and Mail | news.google.com • |
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in ... | news.google.com • |
Ocugen Inc. stock rises Friday, outperforms market | news.google.com • |
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? | news.google.com • |
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? | news.google.com • |
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting | globenewswire.com • |
Profile
...
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-03 | 2024-03 | -0.06 | N/A | N/A | N/A |
2024-04-16 | 2023-12 | 0 | -0.04 | N/A | N/A |
2023-11-09 | 2023-09 | -0.08 | -0.06 | 0.02 | 25.00% |
2023-08-21 | 2023-06 | -0.08 | -0.1 | -0.02 | -25.00% |
2023-05-05 | 2023-03 | -0.11 | -0.07 | 0.04 | 36.36% |
2023-02-28 | 2022-12 | -0.11 | -0.1 | 0.01 | 9.09% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-30 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-07 | Chardan Capital | Upgrade | Buy | |
2023-04-16 | HC Wainwright & Co. | Upgrade | Buy | |
2023-04-13 | Chardan Capital | Upgrade | Buy | |
2023-02-28 | Chardan Capital | Upgrade | Neutral | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-08-10 | CASTILLO KIRSTEN | Director | 50.00K | Sale |
2023-01-02 | CRESPO JESSICA | Officer | 163.39K | Stock Award(Grant) |
2021-05-24 | FERNANDES PRABHAVATHI | Director | 0.00 | Sale |
2021-11-01 | KOMPELLA UDAY B. | Director | 0.00 | Sale |
2022-10-05 | KUMAR RAMESH | Director | 0.00 | Sale |
2023-02-15 | MUSUNURI SHANKAR PH.D | Chief Executive Officer | 3.34M | Sale |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 11.81M | 6.41M | 4.60% |
2023-06-29 | Luminus Management, LLC | 4.08M | 2.22M | 1.59% |
2023-06-29 | GMT Capital Corp | 3.92M | 2.13M | 1.53% |
2023-06-29 | Blackrock Inc. | 3.91M | 2.12M | 1.52% |
2023-06-29 | JP Morgan Chase & Company | 3.04M | 1.65M | 1.19% |
2023-06-29 | Millennium Management Llc | 3.02M | 1.64M | 1.18% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 7.60M | 4.13M | 2.96% |
2023-06-29 | Vanguard Extended Market Index Fund | 3.06M | 1.66M | 1.19% |
2023-05-30 | Fidelity Extended Market Index Fund | 1.07M | 490.29K | 0.42% |
2023-05-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 921.56K | 423.92K | 0.36% |
2023-05-30 | Vanguard Health Care Index Fund | 738.21K | 339.58K | 0.29% |
2023-05-30 | Vanguard Russell 2000 Index Fund | 597.25K | 274.74K | 0.23% |
Split
...
Split | Date |
---|---|
1 : 60 | 2019-09-30 |
This topic has been deleted. Only users with topic management privileges can see it.
-
The Globe and Mail
news.google.com • -
Ocugen Inc. stock rises Friday, outperforms market
news.google.com • -
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
news.google.com • -
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
news.google.com • -
An Approval by WHO Would Not Help Ocugen
news.google.com • -
Ocugen Inc. stock remains steady Thursday, still outperforms market
news.google.com • -
Ocugen Inc. stock falls Wednesday, underperforms market
news.google.com • -
Ocugen Inc. stock rises Tuesday, still underperforms market
news.google.com • -
Chardan Capital Boosts Ocugen (NASDAQ:OCGN) Price Target to $5.00
news.google.com • -
Ocugen (OCGN) Price Target Decreased by 15.79% to 5.44
news.google.com • -
The Globe and Mail
news.google.com •